The Financial Times: Approval of Biogen Alzheimer’s drug reignites ‘amyloid’ debate
Scientists at UC say restoring a brain protein, not removing amyloid plaques, should be the target
The debate over a new drug to treat Alzheimer's is still going strong, with many experts rebutting the science behind its recent FDA approval. One of the most vocal voices objecting to the new drug is UC's Alberto Espay, MD.
“The FDA approval will stimulate further investments into a hypothesis that should have long ago been falsified,” Espay told The Finanical Times.
Espay and a team of researchers at UC and the Karolinska Institute in Sweden back his position with their recent, and highly publicized study, pointing to a different target for the treatment of Alzheimer's disease.
Read The Financial Times article, which has been reprinted in several international news outlets, includinh Kenya News.
Read more about Espay and the UC-led study.
Featured image at top of Alberto Espay, MD. Photo/Colleen Kelley/UC Creative + Brand
Impact Lives Here
The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.